Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. by Andrews, Ross M. et al.
CDI Vol 29 No 3 2005 283
 Article
Infl uenza and pneumococcal vaccine coverage 
among a random sample of hospitalised 
persons aged 65 years or more, Victoria
Ross M Andrews,1,2 Susan A Skull,3 Graham B Byrnes,4 Donald A Campbell,5 Joy L Turner,6 Peter B McIntyre,7 
Heath A Kelly8
Abstract
This study was undertaken to assess the uptake of infl uenza and pneumococcal vaccination based on 
provider records of the hospitalised elderly, a group at high risk of infl uenza and pneumococcal disease. 
The study used a random sample of 3,204 admissions at two Victorian teaching hospitals for patients, 
aged 65 years or more who were  discharged between 1 April 2000 and 31 March 2002. Information 
on whether the patient had received an infl uenza vaccination within the year prior to admission or 
pneumococcal vaccination within the previous fi ve years was ascertained from the patient’s nominated 
medical practitioner/vaccine provider. Vaccination records were obtained from providers for 82 per 
cent (2,804/2,934) of eligible subjects. Infl uenza vaccine coverage was 70.9 per cent (95% CI 68.9–72.9), 
pneumococcal coverage was 52.6 per cent (95% CI 50.4–54.8) and 46.6 per cent (95% CI 44.4–48.8) had 
received both vaccines. Coverage for each vaccine increased seven per cent over the two study years. 
For pneumococcal vaccination, there was a marked increase in 1998 coinciding with the introduction of 
Victoria’s publicly funded program. Infl uenza and pneumococcal vaccine coverage in eligible hospital-
ised adults was similar to, but did not exceed, estimates in the general elderly population. Pneumococcal 
vaccination coverage refl ected the availability of vaccine through Victoria’s publicly funded program. 
A nationally funded pneumococcal vaccination program for the elderly, as announced recently, should 
improve coverage. However, these data highlight the need for greater awareness of pneumococcal vac-
cine among practitioners and for systematic recording of vaccination status, as many of these subjects 
will soon become eligible for revaccination. Commun Dis Intell 2005;29:283–288.
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Background
Every Australian aged 65 years or more is consid-
ered to be at an increased risk of infl uenza and inva-
sive pneumococcal disease, with the risk of adverse 
outcomes likely to be even greater among the hospi-
talised elderly due to other comorbidities.1 Infl uenza 
and 23-valent polysaccharide pneumococcal vac-
cines (23vPPV) are both recommended for people 
in this age group (annually for infl uenza but only one 
dose with a single revaccination fi ve years later for 
23vPPV).1 The infl uenza vaccine has been free for all 
elderly Australians under the national immunisation 
program since 1999 while 23vPPV was added to the 
national program in 2005.2 Although not nationally 
funded, a state based program of free 23vPPV for 
the elderly has operated in Victoria since 1998.3
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Two national telephone surveys have estimated infl u-
enza and pneumococcal vaccine coverage based 
on self-report. In 2000, infl uenza vaccine coverage 
among persons aged 65 years or more in Victoria 
was reported at 75 per cent with 40 per cent having 
received 23vPPV within the previous fi ve years.4 In the 
following year, infl uenza vaccination coverage among 
elderly Victorians was estimated at 81 per cent.5
Since self-reported pneumococcal vaccination sta-
tus is unreliable6–9 we aimed to assess the uptake 
of pneumococcal and infl uenza vaccines based 
on provider records. We estimated coverage in 
Victoria, where both vaccines are publicly funded, 
among a cohort of hospitalised persons aged 
65 years or more.
Methods
We determined infl uenza and pneumococcal vac-
cination status from a random sample of persons 
aged 65 years or more who had been discharged 
from the Royal Melbourne Hospital or the Western 
Hospital between 1 April 2000 and 31 March 2002. At 
the conclusion of each month throughout the study 
period, subjects were randomly selected (using a 
random number generator) from a list of persons 
aged ≥65 years who had been discharged from each 
hospital in that month. If the subject appeared on the 
list more than once in any given month (more than 
one discharge recorded for that month), we selected 
one admission at random and excluded other admis-
sions. For repeat admissions over numerous months, 
we retained the fi rst selected admission and excluded 
all subsequent admissions. We also excluded non-
residents of Victoria, those aged <65 years, and day 
admissions for dialysis or chemotherapy (ICD-10-AM 
codes Z49.1, Z49.2 and Z51.1).
We contacted each subject or their next of kin by 
telephone and, after obtaining verbal consent to par-
ticipate, requested permission to contact the subject’s 
general practitioner or other vaccine providers. We 
contacted these providers in writing and asked if they 
had a record of infl uenza vaccine within the year prior 
to admission or pneumococcal vaccination within the 
fi ve years prior to admission. If so, we requested the 
specifi c vaccination date.
Our study was a component of a case-cohort study 
aimed at assessing vaccine effectiveness against 
community-acquired pneumonia. For this reason we 
report vaccination coverage of the cohort in terms 
of protection. Vaccination was considered protec-
tive if it was given between 14 days and one year 
prior to hospital admission for infl uenza vaccine or 
14 days and fi ve years prior for pneumococcal vac-
cine. Subjects for whom the provider indicated the 
vaccine was given but gave no vaccination date, an 
incomplete date or a date within 14 days of admis-
sion were excluded.
Since subjects were selected from a monthly list of 
discharged patients, even if they were selected only 
once, they were more likely to have been selected 
if they had been frequently admitted over the study 
period than if they had been admitted only once. We 
adjusted for this potential bias at the conclusion of 
the data collection period by calculating vaccination 
coverage as a weighted average. The weighting was 
the inverse of the total number of months where the 
subject had at least one discharge recorded from 
the hospital during the study period. We report both 
weighted and unweighted coverage estimates.
We estimated annual infl uenza vaccine coverage 
and 23vPPV coverage within the previous fi ve years. 
Exact 95 per cent confi dence intervals for proportions 
were calculated using Stata 8.0.10 We compared 
23vPPV coverage by year of vaccination from our 
study against the number of 23vPPV doses available 
in Victoria. Vaccine dose data were obtained from 
two sources: 23vPPV prescriptions issued from 1992 
to 2001 by State;11 and 23vPPV doses distributed 
through Victoria’s publicly funded program (i.e. no 
prescription required) from 1998 to 2001 (personal 
communication, Ted Jamieson, Department of Human 
Services, Victoria, March 2003). Our study was 
approved by the Human Research Ethics Committee, 
Royal Melbourne Hospital Research Foundation (ref 
2000.022).
Results
There were 83,280 hospital separations coded for 
persons aged 65 years or more during the two-
year study period of which 27,372 (33%) were day 
admissions for dialysis or chemotherapy and were 
excluded. A further 6,216 (7%) hospital separations 
were excluded as repeat separations for the same 
person in that month. We randomly selected 3,204 
(6%) from the remaining 49,692 separations. The 
proportion of subjects selected from the hospital 
discharge list each month ranged from 5.2 per cent 
to 8.4 per cent, with peaks over winter months cor-
responding to the increase in the number of cases 
selected in the case-cohort study (Figure 1).
Of the 3,204 randomly selected admissions, 202 (6%) 
were excluded because they were repeat admis-
sions for previously selected subjects and 68 (2%) 
were excluded for various other reasons (Figure 2). 
The median age of the remaining 2,934 eligible sub-
jects was 75 years (range 65–102 years) and 51 per 
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cent were male. We ascertained infl uenza vaccina-
tion status from nominated providers for 82 per cent 
(2,408/2,934) of subjects, 23vPPV status for 83 per 
cent (2,448/2,934) and both vaccines for 81 per cent 
(2,380/2,934). There was no difference in age and 
sex distribution between those eligible subjects for 
whom we ascertained vaccination status and those 
for whom we did not (data not shown).
The weighted estimates of vaccine coverage were 
70.9 per cent (95% CI 68.9–72.9) for infl uenza vac-
cination within the year prior to admission, 52.6 per 
cent (95% CI 50.4–54.8) for 23vPPV within fi ve years 
prior to admission, and 46.6 per cent (95% CI44.4–
48.8) for both vaccines. These estimates were virtu-
ally identical to unweighted estimates (unadjusted 
for selection probability), suggesting subjects with 
repeated admissions over the study period did not 
bias the coverage estimate (Table).
Figure 1. Proportion of hospitalisations selected 
from monthly list of discharge diagnoses for 
persons aged 65 years or more, Victoria, 1 April 
2000 to 31 March 2002
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Figure 2. Response rate for ascertainment of infl uenza and pneumococcal vaccination status among 
hospitalised persons aged 65 years or more, Victoria, 1 April 2000 to 31 March 2002
Influenza
vaccine
Pneumococcal
vaccine
270 excluded
202 repeat admits
  26 non-Vic residents
  22 aged <65 years
  20 non-acute admission
353 no response (12.0%)
95 no provider response
(3.2%)
38 excluded-vaccination
date unconfirmed (1.3%)
3,204 admissions selected
2,934 eligible subjects
(100.0%)
94 no provider response
(3.2%)
79 excluded - vaccination
date unconfirmed (2.7%)
2,448 with known
 vaccination status
(83.4%)
2,408 with known
vaccination status
(82.1%)
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Coverage for each vaccine increased from the fi rst 
study year (April 2000-March 2001) to the second 
(April 2001-March 2002). Even though infl uenza vac-
cine coverage was substantially higher, the overall 
increase in coverage was similar for each vaccine: 
7.1 per cent (95% CI 3.1–11.1) for infl uenza vac-
cine, 7.2 per cent (95% CI 2.9–11.5) for 23vPPV 
and 7.9 per cent (95% CI 2.9–11.5) for those who 
had received both vaccines (Table). Comparison of 
vaccine coverage by age group suggests the overall 
increase was evenly distributed across each fi ve-year 
age stratum over 65 years for infl uenza vaccination 
whereas increases in the point estimates for 23vPPV 
were limited to those under 85 years (Figure 3). The 
greatest increase in 23vPPV coverage occurred in 
1998 coinciding with the commencement of Victoria’s 
publicly funded program and peak in vaccine avail-
ability (Figure 4).
Table. Infl uenza and pneumococcal vaccine coverage (weighted and unweighted) among a cohort 
of hospitalised persons aged ≥65 years, Victoria, 1 April 2000 to 31 March 2002, by year of discharge
Vaccination coverage Infl uenza vaccine 23vPPV Both vaccines
% (95%CI) % (95%CI) % (95%CI)
Total (unweighted) 70.7 (68.8–72.5) 52.4 (50.4–54.4) 46.4 (44.4–48.4)
Total (weighted) 70.9 (68.9–72.9) 52.6 (50.4–54.8) 46.6 (44.4–48.8)
Study year 1 (weighted) 67.4 (64.5–70.2) 49.1 (46.1–52.1) 42.8 (39.8–45.8)
Study year 2 (weighted) 74.5 (71.7–77.2) 56.3 (53.2–59.4) 50.7 (47.5–53.9)
Increase (weighted) 7.1 (3.1–11.1) 7.2 (2.9–11.5) 7.9 (3.6–12.3)
Infl uenza vaccine within the year prior to admission, 23vPPV within fi ve years prior to admission.
Weighted coverage estimates adjust for probability of selection (see Methods).
Study year 1 = Subjects discharged between 01/04/2000 and 31/03/2001.
Study year 2 = Subjects discharged between 01/04/2001 and 31/03/2002.
Increase refers to increase in coverage between Study year 1 and Study year 2.
Figure 4. Comparison of 23vPPV coverage 
among a cohort of hospitalised persons aged 
65 years or more against total doses of 23vPPV 
available, Victoria, 1992 to 2001, by study year 
and year of vaccination
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Study year 1 = Subjects discharged between 1 April 2000 and 
31 March 2001.
Study year 2 = Subjects discharged between 1 April 2001 and 
31 March 2002.
PBS (Pharmaceutical Benefi ts Scheme)/RPBS (Repatriation 
Pharmaceutical Benefi ts Scheme)11
Doses distributed under Victoria’s publicly funded program, 
i.e. no prescription required, (personal communication, 
Ted Jamieson, Department of Human Services, Victoria, 
March 2003).
Figure 3. Infl uenza and pneumococcal vaccine 
coverage among a cohort of hospitalised persons 
aged 65 years or more, Victoria, 1 April 2000 
to 31 March 2002, by age group and year of 
discharge
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Discussion
Our study determined infl uenza and pneumococcal 
vaccination status using complete vaccination dates 
from provider records and should therefore be con-
sidered minimum coverage estimates among the 
respondents. Any infl uenza or pneumococcal vaccin-
ations that were not identifi ed could have only increased 
coverage among the respondents. We expect that 
vaccination coverage may be lower among the non-
respondents. A similar study among community based 
elderly in Victoria had a response rate of 72 per cent 
with the estimated pneumococcal coverage revised 
from 57.9 per cent (95% CI 52.0–63.6) to 50.5 per 
cent (44.8–56.1) after accounting for response bias.8 
It should be noted that the response rate in our study 
was substantially higher with 82.1 per cent of eligible 
subjects having a known infl uenza vaccination status 
and 83.4 per cent having a known pneumococcal vac-
cination status.
We found infl uenza vaccine uptake among the 
respondents had increased by seven percentage 
points from 68 per cent during the fi rst study year 
(April 2000–March 2001) to 75 per cent in the sec-
ond year (April 2001–March 2002). Others have also 
found evidence of increased infl uenza coverage in 
community based surveys in Victoria over a similar 
time period,5 although the estimates were higher 
(78% in 2000 and 81% in 2001) and based on self 
report. Given that self-reported infl uenza vaccine 
status is considered to be reliable,6 the lower infl u-
enza vaccination rates in our study may refl ect lower 
overall coverage among the hospitalised elderly.
Like infl uenza vaccine, 23vPPV coverage among 
respon dents also increased by seven percentage 
points between the fi rst study year and the second. 
The increase was roughly equivalent to the amount 
of 23vPPV distributed through Victoria’s publicly 
funded program, which may have also infl uenced the 
increase in infl uenza vaccine coverage because per-
sons requiring 23vPPV would almost certainly have 
been eligible for infl uenza vaccination. The improve-
ment in coverage appeared to be broad based, with 
the point estimate increasing across each fi ve-year 
age stratum over 65 years with the exception of 
23vPPV coverage among subjects over 85 years. Our 
study was limited to a two year observation period 
but it was encouraging that uptake of both vaccines 
had increased among the hospitalised elderly in the 
second year.
Our estimates were consistent with the available 
doses of 23vPPV each year, the greatest increase 
in coverage coinciding with the introduction of 
Victoria’s publicly funded program in 1998 when 
the total number of doses available was greatest. 
We found the increase in 1998 was consistent for 
both those subjects discharged during the fi rst study 
year and those discharged during the second. This 
is further evidence indicating that the introduction of 
Victoria’s publicly funded program has dramatically 
increased coverage even though funding has limited 
the availability of vaccine from year to year.8,12
Our results suggest 53 per cent of the hospitalised 
elderly had received 23vPPV within the fi ve years 
prior to admission, increasing from 49 per cent in 
2000/01 to 56 per cent in 2001/02. In an earlier 
study, MacIntyre, et al reported 23vPPV coverage 
among a non-random sample of elderly patients at 
the Royal Melbourne Hospital had increased from 
four per cent in 1997 to 41 per cent in 1998.13 As 
previously noted, a similar population-based survey 
in Victoria, which also confi rmed coverage from pro-
vider records, found very similar results to those of 
our study with 23vPPV coverage among the elderly 
of 50.5 per cent (95% CI 44.8–56.1) in 2000 after 
adjusting for response bias.8 This suggests vaccine 
coverage among hospitalised patients is similar to 
but not greater than vaccine coverage in the com-
munity. It could be expected that persons regularly 
admitted to hospital would have more contact with 
health professionals and therefore be more likely 
to be vaccinated but we found no evidence of this 
as demonstrated by the weighted and unweighted 
coverage estimates being virtually identical.
Victoria’s publicly funded 23vPPV program has led 
to a reduction in the incidence of invasive pneu-
mococcal disease among the elderly in that State.14 
Given that pneumococcal vaccine has been shown 
to be cost-effective for people aged 65 years or more 
in other countries15–17 and is likely to be of similar 
benefi t to infl uenza vaccine in this age group,18 our 
study provides support for the introduction of a fully 
funded national 23vPPV program for the elderly as 
announced recently.2 Our data suggests a national 
23vPPV program may also provide further impetus 
to improve infl uenza vaccination uptake among the 
elderly.
The hospitalised elderly are a group at particularly 
high-risk from infl uenza and pneumococcal dis-
ease. Both vaccines are now available free to all 
Australians aged 65 years or more. Every opportu-
nity, including hospital admission, should be taken 
to review vaccination status among this age group 
and immunise as appropriate.
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